Although targeting mutated TP53 in therapy is challenging, there are emerging possibilities, such as p53-targeting cancer vaccines, MDM2 inhibitors (a negative regulator of p53), and monoclonal antibodies that target mutated p53 epitopes [6,54,55]. Here, MDM2 is linked to cancer.